FulvestrantA Review of its Use in the Management of Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women

被引：0
作者：
Jamie D. Croxtall
Kate McKeage
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2011年 / 71卷
关键词：
Tamoxifen; Postmenopausal Woman; Anastrozole; Exemestane; Fulvestrant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Fulvestrant (Faslodex®) is an intramuscularly administered steroidal estrogen receptor antagonist that is devoid of any known estrogen agonist effects. It is indicated as second-line therapy for the treatment of postmenopausal women with hormone receptor-positive advanced breast cancer who have progressed following prior endocrine therapy.
引用
收藏
页码：363 / 380
页数：17
相关论文
共 194 条
  • [1] Peto R(2000)UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years [letter] Lancet 355 1822-47
  • [2] Travis RC(2003)Oestrogen exposure and breast cancer risk Breast Cancer Res 5 239-72
  • [3] Key TJ(2001)The multifaceted mechanisms of estradiol and estrogen receptor signaling J Biol Chem 276 36869-31
  • [4] Hall JM(2007)Estrogen receptors: how do they signal and what are their targets Physiol Rev 87 905-36
  • [5] Couse JF(2002)Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database Breast Cancer Res Treat 76 27-20
  • [6] Korach KS(2005)Sex steroid-producing enzymes in human breast cancer Endocr Relat Cancer 12 701-53
  • [7] Heldring N(2007)Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer Drugs 67 2335-60
  • [8] Pike A(2002)Fulvestrant (Faslodex): current status in the therapy of breast cancer Expert Rev Anticancer Ther 2 151-705
  • [9] Andersson S(2006)What clinicians need to know about antioestrogen resistance in breast cancer therapy Eur J Cancer 42 2692-304
  • [10] Anderson WF(2001)Endocrine therapy in the treatment of metastatic breast cancer Semin Oncol 28 291-48
12345678910